Cargando…

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer

SIMPLE SUMMARY: High-grade serous ovarian carcinoma (HGSC) could be analyzed with a molecular stratification defined by different genomic instability signatures associated with specific mutational process and prognostic biomarkers. Immune infiltrate is known to be a robust biomarker in HGSC. We aime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lecuelle, Julie, Boidot, Romain, Mananet, Hugo, Derangère, Valentin, Albuisson, Juliette, Goussot, Vincent, Arnould, Laurent, Tharin, Zoé, Ray Coquard, Isabelle, Ghiringhelli, François, Truntzer, Caroline, Fumet, Jean-David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430641/ https://www.ncbi.nlm.nih.gov/pubmed/34503204 http://dx.doi.org/10.3390/cancers13174394

Ejemplares similares

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing
por: Galland, Loïck, et al.
Publicado: (2022)

Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use
por: Chevrier, Sandy, et al.
Publicado: (2022)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma
por: Lecuelle, Julie, et al.
Publicado: (2021)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
por: Ledys, Fanny, et al.
Publicado: (2018)

Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients
por: Mazel, Benoit, et al.
Publicado: (2023)

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
por: Galland, Loïck, et al.
Publicado: (2021)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization
por: Courtaut, Flavie, et al.
Publicado: (2015)

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022)

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
por: Chevrier, Sandy, et al.
Publicado: (2021)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Utility of exome sequencing in routine care for metastatic colorectal cancer
por: D'Agay, Melchior De Giraud, et al.
Publicado: (2021)

Implementation and use of whole exome sequencing for metastatic solid cancer
por: Réda, Manon, et al.
Publicado: (2020)

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report
por: Roussot, Nicolas, et al.
Publicado: (2023)

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2018)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
por: Mabrouk, Nesrine, et al.
Publicado: (2023)

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images
por: Le Page, Anne Laure, et al.
Publicado: (2021)

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
por: Kaderbhaï, Courèche, et al.
Publicado: (2019)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Induction of pyroptosis in colon cancer cells by LXRβ
por: Rébé, Cédric, et al.
Publicado: (2015)

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
por: Galland, Loïck, et al.
Publicado: (2021)

Quantification of HTLV-1 Clonality and TCR Diversity
por: Laydon, Daniel J., et al.
Publicado: (2014)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

Pitfalls in TCR gene clonality testing: teaching cases
por: Groenen, Patricia J. T. A., et al.
Publicado: (2008)

Predominant Role of T Cell Receptor (TCR)-α Chain in Forming Preimmune TCR Repertoire Revealed by Clonal TCR Reconstitution System
por: Yokosuka, Tadashi, et al.
Publicado: (2002)

Transcriptome analysis of T(H)2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice
por: Bruchard, Mélanie, et al.
Publicado: (2015)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
por: Ghiringhelli, François, et al.
Publicado: (2019)

Influence of primary tumor location and resection on survival in metastatic colorectal cancer
por: Tharin, Zoé, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tdd1jvrvlbok52lt45pde6qfdt